We use drugs already approved for other indications. Having already met safety criteria, they compete on efficacy rather than safety, and dramatically cut the cost and time to reach patients.
We combine chemotherapy drugs with molecules that enhance their action. This lowers the effective chemotherapy dose and, with it, the toxicity for the patient.
We deliver our combinations in biocompatible nanoemulsions that help the treatment reach its target and increase its efficacy.
Lead program
One of the most common paediatric cancers and among the most resistant to chemotherapy. Our therapy combines a chemotherapy agent with a molecule that enhances its effect: a synergy that significantly reduces the effective dose and toxicity.
In in vivo models, the combination enhanced the reduction in tumour volume.
Lower effective chemotherapy dose and fewer toxic effects.
Near-complete suppression of lung metastases in animal models.
In 3D models, the nanoemulsion treatment outperformed its free form.
Pipeline